Cargando…
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
Although immunotherapy can offer profound clinical benefit for patients with a variety of difficult-to-treat cancers, many tumors either do not respond to upfront treatment with immune checkpoint inhibitors (ICIs) or progressive/recurrent disease occurs after an interval of initial control. Improved...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016262/ https://www.ncbi.nlm.nih.gov/pubmed/36918220 http://dx.doi.org/10.1136/jitc-2022-005920 |
_version_ | 1784907369849815040 |
---|---|
author | Rizvi, Naiyer Ademuyiwa, Foluso O Cao, Z Alexander Chen, Helen X Ferris, Robert L Goldberg, Sarah B Hellmann, Matthew D Mehra, Ranee Rhee, Ina Park, Jong Chul Kluger, Harriet Tawbi, Hussein Sullivan, Ryan J |
author_facet | Rizvi, Naiyer Ademuyiwa, Foluso O Cao, Z Alexander Chen, Helen X Ferris, Robert L Goldberg, Sarah B Hellmann, Matthew D Mehra, Ranee Rhee, Ina Park, Jong Chul Kluger, Harriet Tawbi, Hussein Sullivan, Ryan J |
author_sort | Rizvi, Naiyer |
collection | PubMed |
description | Although immunotherapy can offer profound clinical benefit for patients with a variety of difficult-to-treat cancers, many tumors either do not respond to upfront treatment with immune checkpoint inhibitors (ICIs) or progressive/recurrent disease occurs after an interval of initial control. Improved response rates have been demonstrated with the addition of ICIs to cytotoxic therapies, leading to approvals from the US Food and Drug Administration and regulatory agencies in other countries for ICI−chemotherapy combinations in a number of solid tumor indications, including breast, head and neck, gastric, and lung cancer. Designing trials for patients with tumors that do not respond or stop responding to treatment with immunotherapy combinations, however, is challenging without uniform definitions of resistance. Previously, the Society for Immunotherapy of Cancer (SITC) published consensus definitions for resistance to single-agent anti-programmed cell death protein 1 (PD-1). To provide guidance for clinical trial design and to support analyses of emerging molecular and cellular data surrounding mechanisms of resistance to ICI-based combinations, SITC convened a follow-up workshop in 2021 to develop consensus definitions for resistance to multiagent ICI combinations. This manuscript reports the consensus clinical definitions for combinations of ICIs and chemotherapies. Definitions for resistance to ICIs in combination with targeted therapies and with other ICIs will be published in companion volumes to this paper. |
format | Online Article Text |
id | pubmed-10016262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-100162622023-03-16 Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy Rizvi, Naiyer Ademuyiwa, Foluso O Cao, Z Alexander Chen, Helen X Ferris, Robert L Goldberg, Sarah B Hellmann, Matthew D Mehra, Ranee Rhee, Ina Park, Jong Chul Kluger, Harriet Tawbi, Hussein Sullivan, Ryan J J Immunother Cancer Position Article and Guidelines Although immunotherapy can offer profound clinical benefit for patients with a variety of difficult-to-treat cancers, many tumors either do not respond to upfront treatment with immune checkpoint inhibitors (ICIs) or progressive/recurrent disease occurs after an interval of initial control. Improved response rates have been demonstrated with the addition of ICIs to cytotoxic therapies, leading to approvals from the US Food and Drug Administration and regulatory agencies in other countries for ICI−chemotherapy combinations in a number of solid tumor indications, including breast, head and neck, gastric, and lung cancer. Designing trials for patients with tumors that do not respond or stop responding to treatment with immunotherapy combinations, however, is challenging without uniform definitions of resistance. Previously, the Society for Immunotherapy of Cancer (SITC) published consensus definitions for resistance to single-agent anti-programmed cell death protein 1 (PD-1). To provide guidance for clinical trial design and to support analyses of emerging molecular and cellular data surrounding mechanisms of resistance to ICI-based combinations, SITC convened a follow-up workshop in 2021 to develop consensus definitions for resistance to multiagent ICI combinations. This manuscript reports the consensus clinical definitions for combinations of ICIs and chemotherapies. Definitions for resistance to ICIs in combination with targeted therapies and with other ICIs will be published in companion volumes to this paper. BMJ Publishing Group 2023-03-14 /pmc/articles/PMC10016262/ /pubmed/36918220 http://dx.doi.org/10.1136/jitc-2022-005920 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Position Article and Guidelines Rizvi, Naiyer Ademuyiwa, Foluso O Cao, Z Alexander Chen, Helen X Ferris, Robert L Goldberg, Sarah B Hellmann, Matthew D Mehra, Ranee Rhee, Ina Park, Jong Chul Kluger, Harriet Tawbi, Hussein Sullivan, Ryan J Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy |
title | Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy |
title_full | Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy |
title_fullStr | Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy |
title_full_unstemmed | Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy |
title_short | Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy |
title_sort | society for immunotherapy of cancer (sitc) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy |
topic | Position Article and Guidelines |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016262/ https://www.ncbi.nlm.nih.gov/pubmed/36918220 http://dx.doi.org/10.1136/jitc-2022-005920 |
work_keys_str_mv | AT rizvinaiyer societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy AT ademuyiwafolusoo societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy AT caozalexander societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy AT chenhelenx societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy AT ferrisrobertl societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy AT goldbergsarahb societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy AT hellmannmatthewd societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy AT mehraranee societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy AT rheeina societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy AT parkjongchul societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy AT klugerharriet societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy AT tawbihussein societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy AT sullivanryanj societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy |